BHC - Bausch Health Cos Inc Stock Price, Fair Value and News

$4.56-0.11 (-2.36%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BHC Price Action

Last 7 days

-3.0%

Last 30 days

5.1%

Last 90 days

-28.5%

Trailing 12 Months

-36.0%

BHC RSI Chart

BHC Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-42.13

Price/Sales (Trailing)

0.17

EV/EBITDA

7.76

Price/Free Cashflow

1.37

BHC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BHC Fundamentals

BHC Revenue

Revenue (TTM)

9.7B

Rev. Growth (Yr)

4.92%

Rev. Growth (Qtr)

-11.72%

BHC Earnings

Earnings (TTM)

-40.0M

Earnings Growth (Yr)

9.38%

Earnings Growth (Qtr)

-162.37%

BHC Profitability

EBT Margin

1.94%

Return on Equity

16.67%

Return on Assets

-0.15%

Free Cashflow Yield

72.81%

BHC Investor Care

Dividend Yield

24.15%

Dividend/Share (TTM)

1.28

Shares Dilution (1Y)

0.75%

Diluted EPS (TTM)

-0.11

BHC Alerts

Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	9.7B	0	0	0
2024	9.0B	9.2B	9.5B	9.6B
2023	8.2B	8.3B	8.5B	8.8B
2022	8.3B	8.2B	8.1B	8.1B
2021	8.0B	8.5B	8.5B	8.4B
2020	8.6B	8.1B	8.0B	8.0B
2019	8.4B	8.4B	8.5B	8.6B
2018	8.6B	8.5B	8.4B	8.4B
2017	9.4B	9.2B	9.0B	8.7B
2016	10.6B	10.3B	10.0B	9.7B
2015	8.5B	9.2B	9.9B	10.4B
2014	6.6B	7.5B	8.0B	8.2B
2013	3.7B	4.0B	4.6B	5.8B
2012	2.7B	2.9B	3.2B	3.5B
2011	1.5B	1.9B	2.3B	2.4B
2010	0	912.0M	907.7M	1.2B

Get all data in R, Python etc through our Historical Stock Data APIs

About Bausch Health Cos Inc

Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.

CEO	Mr. Thomas J. Appio
WEBSITE	bauschhealth.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	19900

Bausch Health Cos Inc Frequently Asked Questions

What is the ticker symbol for Bausch Health Cos Inc? What does BHC stand for in stocks?

BHC is the stock ticker symbol of Bausch Health Cos Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bausch Health Cos Inc (BHC)?

As of Wed May 14 2025, market cap of Bausch Health Cos Inc is 1.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BHC stock?

You can check BHC's fair value in chart for subscribers.

Is Bausch Health Cos Inc a good stock to buy?

The fair value guage provides a quick view whether BHC is over valued or under valued. Whether Bausch Health Cos Inc is cheap or expensive depends on the assumptions which impact Bausch Health Cos Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BHC.

What is Bausch Health Cos Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 14 2025, BHC's PE ratio (Price to Earnings) is -42.13 and Price to Sales (PS) ratio is 0.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BHC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bausch Health Cos Inc's stock?

In the past 10 years, Bausch Health Cos Inc has provided -0.323 (multiply by 100 for percentage) rate of return.